

LSP LIFE SCIENCES FUND N.V.

2023 Annual Report publication, convening of the AGM and initiation of the liquidation process

AMSTERDAM – 18:00h CEST, 18 April 2024 / LSP Life Sciences Fund N.V. (the “**Company**”) today published its annual report for the year 2023. The Company has also convened its annual general meeting to be held on 31 May 2024 at 10:00 CEST (the “**AGM**”) at the offices of the Company at the Johannes Vermeerplein 9, Amsterdam, the Netherlands.

The convening notice and corresponding documents including the agenda with explanatory notes and all other documents relevant for the AGM (the “**AGM Documents**”) can be inspected during regular office hours at the offices of the Company, Johannes Vermeerplein 9, 1071 DV Amsterdam, from the date hereof until the close of the AGM. Shareholders and other persons with meeting rights can obtain copies of the AGM Documents free of charge at the aforementioned offices of the Company (bas.vaessen@eqtpartners.com). The AGM Documents can also be downloaded from the Company's website: <http://www.lspvc.com/funds/public.html>.

The full version of the Company's 2023 annual report is available on the Company's website: <http://www.lspvc.com/funds/public.html>.

The Company's investment strategy to buy minority interests in publicly listed companies, no longer falls within the active and private investment strategy that all other funds managed within the EQT Group, adhere to. The Company therefore proposes to put to vote at the AGM the resolution to dissolve the Company with effect from 15 June 2024 and appoint the Company's managing director, LSP Advisory B.V., as the Company's liquidator (*vereffenaar*) and custodian (*bewaarder*) of the Company's books and records. In accordance with the articles of association of the Company (the “**Articles of Association**”), the liquidation shall be effected under the supervision of the Company's supervisory board.

As, upon adoption of the proposal to dissolve the Company, the Company's dissolution shall become effective on 15 June 2024, the last day of trading with respect to the shares in the capital of the Company (the “**Shares**”) is expected to be 14 June 2024. This means that sale and purchase orders to be executed prior to the delisting of the Shares must be received by the agent of the Company for Euronext trading purposes (being: CACEIS) before 16:00 CEST on 13 June 2024. As of 15 June 2024, trading in the Shares shall be suspended until the Shares are delisted from Euronext Amsterdam, which is expected to occur as of 17 June 2024. This means that, (i) as of and after 15 June 2024 Shares can no longer be sold or purchased through placing trading orders on Euronext Amsterdam (only through directed book-entry transfers from one securities account to another) and (ii) as of and after 17 June 2024 Shares can only be transferred through the execution of a notarial deed.

If this proposal is adopted, the Company's liquidator will declare an advance liquidation distribution to the shareholders of the Company of approximately EUR 250 per Share, which shall be payable on 19 June 2024. The ex-dividend date for this distribution shall be 17 June 2024. If following completion of the liquidation procedure the Company shall have any remaining assets, the Company's shareholders shall receive a final liquidation distribution. The amount and timing of that final liquidation distribution (if any) is uncertain and, if such a distribution will be made, the Company will announce this on its website and through the publication of a press release.

Indicative timetable

The timetable below sets forth the anticipated timeline for the Company's liquidation process:

AGM	31 May 2024
Cut-off time for sale and purchase orders to be executed on the last day of trading of the Shares	13 June 2024 before 16:00 CEST
Last day of trading of the Shares	14 June 2024
Dissolution becomes effective; start of liquidation process	15 June 2024
Expected delisting of the Shares	17 June 2024, before opening
Ex-dividend date for advance liquidation distribution	17 June 2024
Record date for advance liquidation distribution	18 June 2024
Payment date for advance liquidation distribution	19 June 2024
Public filing and announcement of liquidation accounts and distribution plan	End of June 2024
Creditor opposition period	End of June 2024 to End of August 2024
Completion of the liquidation and announcement and payment of final liquidation distribution (if any)	Mid-September 2024

Potential suspension of trading prior to AGM

As a listed open end investment fund, the Company is, in principle, subject to the restrictions set out in the prospectus with respect to the Company dated 26 June 2015 (the “**Prospectus**”) and restrictions under the articles of association of the Company (the “**Articles of Association**”) and applicable law, willing to sell and repurchase Shares on each trading day. In accordance with Dutch law and the Articles of Association, the Company's issued and outstanding share capital must always be at least ten percent (10%) of the Company's authorised share capital. As the Company's authorised share capital comprises 1,000,000 Shares, the Company will not be allowed to repurchase Shares to the extent this would cause the number of issued and outstanding Shares to become less than 100,000. In accordance with the Prospectus, the Company may in such case suspend the repurchase of Shares. In order to enable the Company to repurchase additional Shares prior to the delisting of the Shares becoming effective, a resolution shall be put to vote at the AGM to amend the Articles of Association by decreasing the authorised share capital of the Company.

In view of said restrictions, it may be possible that the Company must suspend the repurchase of the Shares prior to the AGM. In that case, subject to the adoption of the resolution to amend the Articles of Association implementation of such amendment, the Company will recommence the repurchase of the Shares as soon as possible after the AGM in order to execute any further repurchases prior to the delisting of the Shares.

LSP Life Sciences Fund N.V.

Bas Vaessen (General Counsel EQT Life Sciences)

+31 (0) 20 664 55 00

Bas.Vaessen@eqtpartners.com

This press release contains information that qualifies or may have qualified as inside information within the meaning of article 7(1) of the Market Abuse Regulation (Regulation (EU) No 596/2014).

Certain statements in this press release are “forward-looking statements” including those that refer to management’s plans and expectations for future operations, prospects and financial condition. Words such as “strategy,” “expects,” “plans,” “anticipates,” “believes,” “will,” “continues,” “estimates,” “intends,” “projects,” “goals,” “targets” and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the LSP Life Sciences Fund N.V. manager only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of the LSP Life Sciences Fund N.V. manager. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting the LSP Life Sciences Fund N.V.’s business. The LSP Life Sciences Fund N.V. manager expressly disclaims any intent or obligation to update any forward-looking statements herein except as required by law.